Sexual relations, a complex and multifaceted aspect of human life, are crucial for emotional and physical well-being. Unfortunately, the problem of erectile dysfunction (ED) has emerged as a frequent and highly significant issue that threatens to mar this vital aspect of human life. Professionals in the field have been tirelessly researching and exploring the best ways to tackle this problem. With the advent of the digital era, information regarding the topic has become ubiquitous, with specialized master classes, seminars, and conferences dedicated to finding a solution.
ED is not exclusive to any particular demographic; every male, from adolescents to adults, is at risk. Sadly, 160 million people worldwide, including 10 million Russians, are already suffering from the disease. The situation is worsened by the steady increase in risk factors, such as cardiovascular diseases and diabetes mellitus, that plague modern society. Furthermore, chronic fatigue, stress, and inadequate nutrition all contribute to the development of ED.
In the face of this adversity, researchers have been exploring different treatment options to tackle ED, with phosphodiesterase inhibitors emerging as the most viable option. Among them, sildenafil has been the most extensively studied and time-tested option to date. To mitigate the potential duration of side effects, sildenafil is often preferred as a short-acting drug and is widely recommended as the first-line drug for treating ED by the European Association of Urology.